FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176963304> ?p ?o ?g. }

• W3176963304 endingPage "427" @default.
• W3176963304 startingPage "417" @default.
• W3176963304 abstract "BackgroundAcute kidney injury (AKI) is common in the perioperative transplant period and is associated with poor outcomes. Few studies reported a reduction in AKI incidence with terlipressin therapy by counteracting the hemodynamic alterations occurring during liver transplantation. However, the effect of terlipressin on posttransplant outcomes has not been systematically reviewed.MethodsA comprehensive search of electronic databases was performed. Studies reporting the use of terlipressin in the perioperative period of living donor liver transplantation were included. We expressed the dichotomous outcomes as risk ratio (RR, 95% confidence interval [CI]) using the random effects model. The primary aim was to assess the posttransplant risk of AKI. The secondary aims were to assess the need for renal replacement therapy (RRT), vasopressors, effect on hemodynamics, blood loss during surgery, hospital and intensive care unit (ICU) stay, and in-hospital mortality.ResultsA total of nine studies reporting 711 patients (309 patients in the terlipressin group and 402 in the control group) were included for analysis. Terlipressin was administered for a mean duration of 53.44 ± 28.61 h postsurgery. The risk of AKI was lower with terlipressin (0.6 [95% CI, 0.44–0.8]; P = 0.001). However, on sensitivity analysis including only four randomized controlled trials (I2 = 0; P = 0.54), the risk of AKI was similar in both the groups (0.7 [0.43–1.09]; P = 0.11). The need for RRT was similar in both the groups (0.75 [0.35–1.56]; P = 0.44). Terlipressin therapy reduced the need for another vasopressor (0.34 [0.25–0.47]; P < 0.001) with a concomitant rise in mean arterial pressure and systemic vascular resistance by 3.2 mm Hg (1.64–4.7; P < 0.001) and 77.64 dyne cm−1.sec−5 (21.27–134; P = 0.007), respectively. Blood loss, duration of hospital/ICU stay, and mortality were similar in both groups.ConclusionsPerioperative terlipressin therapy has no clinically relevant benefit. Acute kidney injury (AKI) is common in the perioperative transplant period and is associated with poor outcomes. Few studies reported a reduction in AKI incidence with terlipressin therapy by counteracting the hemodynamic alterations occurring during liver transplantation. However, the effect of terlipressin on posttransplant outcomes has not been systematically reviewed. A comprehensive search of electronic databases was performed. Studies reporting the use of terlipressin in the perioperative period of living donor liver transplantation were included. We expressed the dichotomous outcomes as risk ratio (RR, 95% confidence interval [CI]) using the random effects model. The primary aim was to assess the posttransplant risk of AKI. The secondary aims were to assess the need for renal replacement therapy (RRT), vasopressors, effect on hemodynamics, blood loss during surgery, hospital and intensive care unit (ICU) stay, and in-hospital mortality. A total of nine studies reporting 711 patients (309 patients in the terlipressin group and 402 in the control group) were included for analysis. Terlipressin was administered for a mean duration of 53.44 ± 28.61 h postsurgery. The risk of AKI was lower with terlipressin (0.6 [95% CI, 0.44–0.8]; P = 0.001). However, on sensitivity analysis including only four randomized controlled trials (I2 = 0; P = 0.54), the risk of AKI was similar in both the groups (0.7 [0.43–1.09]; P = 0.11). The need for RRT was similar in both the groups (0.75 [0.35–1.56]; P = 0.44). Terlipressin therapy reduced the need for another vasopressor (0.34 [0.25–0.47]; P < 0.001) with a concomitant rise in mean arterial pressure and systemic vascular resistance by 3.2 mm Hg (1.64–4.7; P < 0.001) and 77.64 dyne cm−1.sec−5 (21.27–134; P = 0.007), respectively. Blood loss, duration of hospital/ICU stay, and mortality were similar in both groups. Perioperative terlipressin therapy has no clinically relevant benefit." @default.
• W3176963304 created "2021-07-05" @default.
• W3176963304 creator A5011675139 @default.
• W3176963304 creator A5013471768 @default.
• W3176963304 creator A5016210021 @default.
• W3176963304 creator A5019699189 @default.
• W3176963304 creator A5037076474 @default.
• W3176963304 creator A5037219848 @default.
• W3176963304 creator A5049575058 @default.
• W3176963304 creator A5055799027 @default.
• W3176963304 creator A5068418346 @default.
• W3176963304 creator A5069932840 @default.
• W3176963304 creator A5072751544 @default.
• W3176963304 date "2022-03-01" @default.
• W3176963304 modified "2023-10-17" @default.
• W3176963304 title "Prophylactic Perioperative Terlipressin Therapy for Preventing Acute Kidney Injury in Living Donor Liver Transplant Recipients: A Systematic Review and Meta-Analysis" @default.
• W3176963304 cites W1872926097 @default.
• W3176963304 cites W1972278293 @default.
• W3176963304 cites W1989967925 @default.
• W3176963304 cites W2011458442 @default.
• W3176963304 cites W2027377249 @default.
• W3176963304 cites W2028855083 @default.
• W3176963304 cites W2063207704 @default.
• W3176963304 cites W2082138444 @default.
• W3176963304 cites W2098923148 @default.
• W3176963304 cites W2134010282 @default.
• W3176963304 cites W2134833483 @default.
• W3176963304 cites W2159551022 @default.
• W3176963304 cites W2324686306 @default.
• W3176963304 cites W2334146257 @default.
• W3176963304 cites W2334640637 @default.
• W3176963304 cites W2581231725 @default.
• W3176963304 cites W2588681363 @default.
• W3176963304 cites W2605389178 @default.
• W3176963304 cites W2619433242 @default.
• W3176963304 cites W2712272771 @default.
• W3176963304 cites W2728501929 @default.
• W3176963304 cites W2807392623 @default.
• W3176963304 cites W2921383218 @default.
• W3176963304 cites W2934992016 @default.
• W3176963304 cites W2999922512 @default.
• W3176963304 cites W3008227328 @default.
• W3176963304 cites W3093364795 @default.
• W3176963304 cites W3101589986 @default.
• W3176963304 cites W3159795713 @default.
• W3176963304 cites W571628560 @default.
• W3176963304 cites W2541299098 @default.
• W3176963304 doi "https://doi.org/10.1016/j.jceh.2021.06.019" @default.
• W3176963304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35535072" @default.
• W3176963304 hasPublicationYear "2022" @default.
• W3176963304 type Work @default.
• W3176963304 sameAs 3176963304 @default.
• W3176963304 citedByCount "4" @default.
• W3176963304 countsByYear W31769633042023 @default.
• W3176963304 crossrefType "journal-article" @default.
• W3176963304 hasAuthorship W3176963304A5011675139 @default.
• W3176963304 hasAuthorship W3176963304A5013471768 @default.
• W3176963304 hasAuthorship W3176963304A5016210021 @default.
• W3176963304 hasAuthorship W3176963304A5019699189 @default.
• W3176963304 hasAuthorship W3176963304A5037076474 @default.
• W3176963304 hasAuthorship W3176963304A5037219848 @default.
• W3176963304 hasAuthorship W3176963304A5049575058 @default.
• W3176963304 hasAuthorship W3176963304A5055799027 @default.
• W3176963304 hasAuthorship W3176963304A5068418346 @default.
• W3176963304 hasAuthorship W3176963304A5069932840 @default.
• W3176963304 hasAuthorship W3176963304A5072751544 @default.
• W3176963304 hasBestOaLocation W31769633041 @default.
• W3176963304 hasConcept C126322002 @default.
• W3176963304 hasConcept C141071460 @default.
• W3176963304 hasConcept C168563851 @default.
• W3176963304 hasConcept C177713679 @default.
• W3176963304 hasConcept C2776376669 @default.
• W3176963304 hasConcept C2776988256 @default.
• W3176963304 hasConcept C2777214474 @default.
• W3176963304 hasConcept C2779393834 @default.
• W3176963304 hasConcept C2779541074 @default.
• W3176963304 hasConcept C2779609443 @default.
• W3176963304 hasConcept C2780472472 @default.
• W3176963304 hasConcept C2911091166 @default.
• W3176963304 hasConcept C31174226 @default.
• W3176963304 hasConcept C44249647 @default.
• W3176963304 hasConcept C71924100 @default.
• W3176963304 hasConceptScore W3176963304C126322002 @default.
• W3176963304 hasConceptScore W3176963304C141071460 @default.
• W3176963304 hasConceptScore W3176963304C168563851 @default.
• W3176963304 hasConceptScore W3176963304C177713679 @default.
• W3176963304 hasConceptScore W3176963304C2776376669 @default.
• W3176963304 hasConceptScore W3176963304C2776988256 @default.
• W3176963304 hasConceptScore W3176963304C2777214474 @default.
• W3176963304 hasConceptScore W3176963304C2779393834 @default.
• W3176963304 hasConceptScore W3176963304C2779541074 @default.
• W3176963304 hasConceptScore W3176963304C2779609443 @default.
• W3176963304 hasConceptScore W3176963304C2780472472 @default.
• W3176963304 hasConceptScore W3176963304C2911091166 @default.
• W3176963304 hasConceptScore W3176963304C31174226 @default.
• W3176963304 hasConceptScore W3176963304C44249647 @default.
• W3176963304 hasConceptScore W3176963304C71924100 @default.
• W3176963304 hasIssue "2" @default.

• next